University of Nottingham: The TARDIS trial will assess the safety and efficacy of intensive antiplatelet therapy, as compared with guideline antiplatelet therapy in patients at high-risk of stroke recurrenc

Data-sharing agreement from NHS Digital registers of approved data releases, 2014–2019. Evidence status: source reported.

Organisation: University of Nottingham
Source reference: DARS-NIC-148262-PR6G1-v0.1
Jurisdiction: England
Licence: Open Government Licence v3.0, subject to NHS England terms and exclusions

The TARDIS trial will assess the safety and efficacy of intensive antiplatelet therapy, as compared with guideline antiplatelet therapy in patients at high-risk of stroke recurrence.The TARDIS trial will assess the safety and efficacy of intensive antiplatelet therapy, as compared with guideline antiplatelet therapy in patients at high-risk of stroke recurrence.

Register reference: DARS-NIC-148262-PR6G1-v0.1
Agreement period: not published to no end date published
For commercial purposes (as marked in the register): Not stated
Release files listed by NHS England: 10

Data approved

MRIS - Flagging Current Status Report
MRIS - Scottish NHS / Registration
MRIS - Cause of Death Report
MRIS - Cohort Event Notification Report

Objective, as published

Source: https://webarchive.nationalarchives.gov.uk/ukgwa/2019/http://content.digital.nhs.uk/media/24614/Release-Register-March---May-2017/xls/Release_Register__March_-_May_20171.xlsx. Captured 2026-10-30.

Limitations: Agreement as recorded in an NHS Digital register of approved data releases (2014–2019), retrieved from the UK Government Web Archive. That register lists releases made in its period and the agreement's purpose statement as it then stood; it gives no agreement dates, and the agreement may have changed since. Imported only where a paper quotes a reference no current register holds.